“…Tests for low abundance biomarkers such as human prostate specific antigen (PSA) and human pancreatic and gastrointestinal cancer marker (CA 19-9) are routinely used for initial tumor screening, to monitor patient response during cancer therapy, and to help detect recurrence following treatment2, 3. Therefore, there is significant clinical relevance to increase the sensitivity of these tests to facilitate early detection of the onset and recurrence of cancer, since these biomarkers get diluted significantly in blood, especially in early stages of the disease progression.…”